Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis

Author(s):
Mosatafa Rezaei-TaviraniMosatafa Rezaei-TaviraniMosatafa Rezaei-Tavirani ORCID1,*, Dr Vahid MansouriDr Vahid Mansouri1, farshad okhovatianfarshad okhovatianfarshad okhovatian ORCID2, Hojjat Allah AbbaszadehHojjat Allah AbbaszadehHojjat Allah Abbaszadeh ORCID3
1Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Laser Application in Medical Sciences Research Center, Shohada-e-Tajrish Hospital, Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran Email: [email protected]

Journal of Cellular & Molecular Anesthesia:Vol. 7, issue 2; e151416
Published online:Jan 22, 2022
Article type:Research Article
How to Cite:Rezaei-Tavirani M, Mansouri DV, okhovatian F, Abbaszadeh HA. Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis. J Cell Mol Anesth. 2022;7(2):e151416. doi: https://doi.org/10.22037/jcma.v6i4.35656

Abstract

Background: Coronavirus disease 2019 (COVID-19) had a pandemic spread worldwide. Most infected patients had a good prognosis, but some developed severe illnesses, which led to fatalities. It is urgent to define markers that reveal the severity of the disease. This study aimed to introduce the main plasma protein biomarkers involved in severe conditions versus mild infection states.

Materials and Methods: A total of 91 significant differentially expressed proteins (DEPs) in the sera of the patients with the severe condition versus mild states were extracted from an original article. The protein interaction is included in a network designed via STRING database and Cytoscape software to find the critical proteins which differentiate severe conditions versus mild states.

Results: A total of 6 hub nodes identified as critical target proteins were APOB, SERPINA1, CP, ORM1, HASPA8, and VW, according to the Degree value of nodes.

Conclusion: The expression of different biomarkers in the sera of COVID-19 patients can be considered differential markers that separate severe conditions from mild states; however, a more thorough investigation is required.

References

  • 1.
    References are in the PDF file of the article.

Copyright

© 2022, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Dec
2021

Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis

Vahid Mansouri,
Mostafa Rezaei-Tavirani,
farshad okhovatian,
Hojjat Allah Abbaszadeh

Mansouri V, Rezaei-Tavirani M, okhovatian F, Abbaszadeh HA. Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis. J Cell Mol Anesth. 2021;6(4):e149740. doi: https://doi.org/10.22037/jcma.v6i4.35656

17
Aug
2021

Differential Diagnostic Utility of Clinical Laboratory Data in Patients with Severe and Non-severe COVID-19

Ali Hosseinzadeh,
Mohammad Hassan Emamian,
Marzieh Rohani-Rasaf,
Ahmad Khosravi,
Fariba Zare,
Hossein Sheibani
,et al.

Hosseinzadeh A, Emamian MH, Rohani-Rasaf M, Khosravi A, Zare F, et al. Differential Diagnostic Utility of Clinical Laboratory Data in Patients with Severe and Non-severe COVID-19. Shiraz E-Med J. 2021;23(1):e113670. doi: https://doi.org/10.5812/semj.113670

9
Feb
2024
Jundishapur J Microbiol

Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients

Rosa Karimi,
Abdolreza Mohamadnia,
Farzaneh Hosseini,
Naghmeh Bahrami,
Hamidreza Jamaati

Karimi R, Mohamadnia A, Hosseini F, Bahrami N, Jamaati H. Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients. Jundishapur J Microbiol. 2024;17(1):e143611. doi: https://doi.org/10.5812/jjm-143611

9
Jun
2024
Jundishapur J Microbiol

IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19

Sanaz Paikar,
Naghmeh Bahrami,
Robab Rafiei Tabatabai,
Abdolreza Mohamadnia

Paikar S, Bahrami N, Rafiei Tabatabai R, Mohamadnia A. IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19. Jundishapur J Microbiol. 2024;17(5):e144812. doi: https://doi.org/10.5812/jjm-144812

9
Oct
2024
Compr Health Biomed Stud

Investigation of Biochemical and Inflammatory Markers in COVID-19 Patients Hospitalized in the Intensive Care Unit: An Observational Study in Northern Iran

Behnaz Khodabakhshi,
Motahareh Mehghani,
Narges Lashkarbolouk,
Roghieh Golsha,
Sima Besharat,
Mahdi Mazandarani

Khodabakhshi B, Mehghani M, Lashkarbolouk N, Golsha R, Besharat S, et al. Investigation of Biochemical and Inflammatory Markers in COVID-19 Patients Hospitalized in the Intensive Care Unit: An Observational Study in Northern Iran. Compr Health Biomed Stud. 2024;2(3):e149303. doi: https://doi.org/10.5812/chbs-149303

Download PDF513.09 KB

Crossmark

Crossmark

Checking

Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles